Empagliflozin in diabetic cardiomyopathy: elucidating mechanisms, therapeutic potentials, and future directions
- 24 January 2025
- journal article
- review article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-15
Abstract
Diabetic cardiomyopathy (DCM) represents a significant health burden, exacerbated by the global increase in type 2 diabetes mellitus (T2DM). This condition contributes substantially to the morbidity and mortality associated with diabetes, primarily through myocardial dysfunction independent of coronary artery disease. Current treatment strategies focus on managing symptoms rather than targeting the underlying pathophysiological mechanisms, highlighting a critical need for specific therapeutic interventions. This review explores the multifaceted role of empagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, in addressing the complex etiology of DCM. We discuss the key mechanisms by which hyperglycemia contributes to cardiac dysfunction, including oxidative stress, mitochondrial impairment, and inflammation, and how empagliflozin mitigates these effects. Empagliflozin’s effects on reducing hospitalization for heart failure and potentially lowering cardiovascular mortality mark it as a promising candidate for DCM management. By elucidating the underlying mechanisms through which empagliflozin operates, this review underscores its therapeutic potential and paves the way for future research into its broader applications in diabetic cardiac care. This synthesis aims to foster a deeper understanding of DCM and encourage the integration of empagliflozin into treatment paradigms, offering hope for improved outcomes in patients suffering from this debilitating condition.Keywords
This publication has 145 references indexed in Scilit:
- Diabetic Cardiomyopathy: A Brief Summary on Lipid ToxicityESC Heart Failure, 2022
- Dietary Supplementation of Methyl Donor l‐Methionine Alters Epigenetic Modification in Type 2 DiabetesMolecular Nutrition & Food Research, 2019
- Advanced glycation end products reduce the calcium transient in cardiomyocytes by increasing production of reactive oxygen species and nitric oxideFEBS Open Bio, 2017
- Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart diseaseDiabetologia, 2017
- Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 DiabetesCardiovascular Drugs and Therapy, 2017
- Advanced glycation end products: role in pathology of diabetic cardiomyopathyHeart Failure Reviews, 2013
- Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort studyActa Diabetologica, 2013
- Diabetic cardiomyopathy: pathophysiology and clinical featuresHeart Failure Reviews, 2012
- Advanced Glycation Endproduct-Induced Calcium Handling Impairment in Mouse Cardiac MyocytesJournal of Molecular and Cellular Cardiology, 2002
- Diminished Expression of Sarcoplasmic Reticulum Ca2+-ATPase and Ryanodine Sensitive Ca2+Channel mRNA in Streptozotocin-induced Diabetic Rat HeartJournal of Molecular and Cellular Cardiology, 2000